BDX Stock Forecast & Price Target

Becton Dickinson is attractive because the post-separation “New BD” is now a more focused pure-play MedTech franchise with a durable core, more than 60% U.S. revenue exposure, and over 90% consumables revenue supporting recurring demand in a $70B TAM growing at about 5%. Its four business units span essential hospital workflows and higher-growth adjacencies, while the 2025-2026 Waters Reverse Morris Trust should unlock about $4B of cash, ~39% ownership upside, and roughly $345MM of annualized EBITDA synergies. Management’s BD Excellence program and disciplined capital allocation—backed by recent quarterly revenue of $5,274M, 5.6% constant-currency growth, and an operating margin of 28.6%—support the case for margin expansion, stronger cash flow, and mid-single-digit to high-single-digit earnings growth.

Becton Dickinson is facing a cautious fundamental backdrop because management itself has flagged weakening revenue growth at “new BD,” with FY27 pressure from Alaris, China, tariffs, and potential M&A dilution likely to offset benefits from BD Excellence and commercial investment. Even after FQ4 revenue of $5,274M (+5.6% cc) and EPS of $4.15, the company still appears vulnerable to margin compression, including roughly 60bp of y/y margin pressure from the Alaris transition as the business falls from about $500M to $100M in FY27. With more than 60% of revenue tied to the U.S. and heavy exposure to competitive, reimbursement-sensitive segments, the outlook is further weakened by execution risk around the separation, inflation, and supply-chain disruptions.